Clear Cell Renal Cell Carcinoma 2021-2022

• Autres auteurs: Manini, Claudia (Éditeur intellectuel), López, José I. (Éditeur intellectuel)
• Format: Électronique Chapitre de livre
• Langue: anglais
• Publié: Basel MDPI - Multidisciplinary Digital Publishing Institute 2022
• Sujets: Medicine; Clinical & internal medicine; clear cell renal cell carcinoma; prognosis; plasma; PD-1; PD-L1; renal cell carcinoma; immune checkpoint inhibitors; immune related adverse events (irAEs); thyroid; cutaneous; biomarker; DNA methylation; epigenetics; kidney; hypoxia; tumor microenvironment; SCD-1; oleic acid; renal cancer; sunitinib; resistance; miRNA; transcriptome; pathway analysis; nivolumab; tissue slice culture; PD1; T-cells; metastatic clear cell renal cell carcinoma; first-line treatment; immunotherapy; tyrosine kinase inhibitors; combinations; single-cell RNA sequencing; immune landscape; cancer immunotherapy; intra-tumoral heterogeneity; inter-tumoral heterogeneity; inter-metastatic heterogeneity; renal cell cancer; treatment resistance; angiogenesis; adjuvant therapy; prediction model; prognostic factor; clear cell kidney cancer; radiogenomics; radiomics; machine learning; gene expression; cystic tumor; imaging; magnetic resonance; surgery; ddPCR; circulating miRNA; diagnosis; malignancy; histomorphological features; PBRM1; immunohistochemistry; architectural patterns; endothelial cells; translational; immune checkpoint inhibitor; responsiveness; molecular features; multisite tumor sampling; intratumor heterogeneity; clear-cell renal cell carcinoma; disease progression; prognostic factors; biomarkers; RNA sequencing; n/a
• Accès en ligne: DOAB: download the publication; DOAB: description of the publication

Clear cell renal cell carcinoma is currently one of the most interesting areas of study in oncology. Despite the advances made in this field, this tumor continues to be a health problem of major concern in Western societies, seriously affecting public health services. Several characteristics of this...